Profile data is unavailable for this security.
About the company
Dizal Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of biopharmaceuticals. The Company focuses on the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The Company's main drug product is Sunvozertinib, which is used for patients with advanced NSCLC who have had disease progression after previous platinum-containing chemotherapy or are intolerant to platinum-containing chemotherapy and have confirmed EGFR Exon20ins mutation. The Company's other candidate drugs in pipeline are Golidocitinib, DZD8586, DZD2269, DZD1516 and DZD6008. The Company mainly conducts its businesses in the domestic market and overseas markets.
- Revenue in CNY (TTM)389.64m
- Net income in CNY-837.22m
- Incorporated2017
- Employees581.00
- LocationDizal Pharmaceutical Co LtdChina (Shanghai) Pilot Free Trade ZoneBuilding 4, No. 199, 245 Liangjing RoadSHANGHAI 201203ChinaCHN
- Phone+86 2 161095757
- Fax+86 2 158387361
- Websitehttp://www.dizalpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InnoCare Pharma Ltd | 898.92m | -375.51m | 12.73bn | 1.09k | -- | 3.55 | -- | 14.16 | -0.2325 | -0.2325 | 0.537 | 3.86 | 0.0922 | 1.32 | 3.73 | 825,457.90 | -4.02 | -- | -4.78 | -- | 84.50 | -- | -43.57 | -- | 7.65 | -- | 0.1547 | -- | 18.09 | -- | 28.80 | -- | -- | -- |
| Joinn Laboratories China Co Ltd | 2.12bn | -912.86k | 12.97bn | 2.59k | -- | 1.76 | -- | 6.10 | -0.0064 | -0.0064 | 2.82 | 10.68 | 0.2151 | 0.7714 | 7.32 | -- | -0.09 | 8.99 | -0.106 | 11.07 | 31.83 | 46.76 | -0.4184 | 32.01 | 2.85 | 1.25 | 0.0089 | 23.81 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| RemeGen Co Ltd | 1.52bn | -1.55bn | 16.25bn | 3.62k | -- | 8.46 | -- | 10.67 | -2.88 | -2.88 | 2.83 | 4.35 | 0.2712 | 0.4446 | 5.00 | 421,122.40 | -27.65 | -18.66 | -36.21 | -23.69 | 78.65 | 81.64 | -101.95 | -102.21 | 0.9558 | -32.19 | 0.5167 | -- | 40.26 | 141.16 | -51.30 | -- | 59.07 | -- |
| Sinocelltech Group Ltd | 2.45bn | -24.64m | 17.73bn | 2.33k | -- | -- | -- | 7.25 | -0.0553 | -0.0553 | 5.49 | -0.2874 | 0.8146 | 0.4624 | 5.26 | 1,048,041.00 | -0.8674 | -40.17 | -2.70 | -74.63 | 95.83 | 95.42 | -1.06 | -108.20 | 0.588 | 5.45 | 1.05 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Dizal Pharmaceutical Co Ltd | 389.64m | -837.22m | 19.91bn | 581.00 | -- | 46.48 | -- | 51.11 | -2.04 | -2.04 | 0.9471 | 1.03 | 0.235 | 0.4033 | 6.15 | 670,632.10 | -56.00 | -46.02 | -83.89 | -52.99 | 97.17 | 57.53 | -238.28 | -2,081.54 | 1.66 | -193.39 | 0.674 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 3.20bn | 1.30bn | 25.22bn | 1.04k | 19.45 | 5.19 | -- | 7.87 | 2.88 | 2.88 | 7.12 | 10.81 | 0.6811 | 3.60 | 11.38 | 3,068,832.00 | 27.57 | 0.6405 | 30.38 | 0.6933 | 94.43 | 96.42 | 40.47 | 2.54 | 6.89 | -- | 0.0003 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
Data as of Nov 22 2024. Currency figures normalised to Dizal Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
24.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 11.05m | 9.34% |
| China Fund Management Co., Ltd.as of 30 Jun 2024 | 2.80m | 2.37% |
| Huashang Fund Management Co., Ltd.as of 30 Jun 2024 | 2.80m | 2.37% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 2.64m | 2.23% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 1.77m | 1.50% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 1.64m | 1.39% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 1.64m | 1.38% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 1.43m | 1.21% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 1.40m | 1.19% |
| Ping An Fund Management Co., Ltd.as of 30 Jun 2024 | 1.33m | 1.12% |
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
